Drugs / R2R01
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07625553 | Apr 2026 → Apr 2027 expected | acute kidney injury | River 2 Renal Corp. | Recruiting | No outcome recorded |
| Phase 2 | NCT06264310 | Mar → Nov 2024 | congestive heart failure | River 2 Renal Corp. | Completed | No outcome recorded |
| Phase 2 | NCT05875948 | Jun 2023 → Dec 2024 | acute kidney injury, hepatorenal syndrome | River 2 Renal Corp. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R2R01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06264310 ↗ |
| Action | Activate | “Relaxin Agonist R2R01” NCT06264310 ↗ |
| Route | Subcutaneous | “Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.” NCT06264310 ↗ |